Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4,a Randomized Study
Free accessAnnouncementFirst published online April, 2015
Dolutegravir versus Placebo in Subjects Harbouring HIV-1 with Integrase Inhibitor Resistance Associated Substitutions: 48-Week Results from VIKING-4,a Randomized Study
The Phase III VIKING-3 study demonstrated that dolutegravir (DTG) 50 mg twice daily was efficacious in antiretroviral therapy (ART)-experienced subjects habouring raltegravir- and/or elvitegravir-resistant HIV-1. VIKING-4 (ING116529) included a placebo-controlled 7-day monotherapy phase to demonstrate that short-term antiviral activity was attributable to DTG.
Methods
VIKING-4 is a Phase III randomized, double-blind study in therapy-experienced adults with integrase inhibitor (INI)-resistant virus randomized to DTG 50 mg twice daily or placebo while continuing their failing regimen (without raltegravir or elvitegravir) for 7 days (clinicaltrials.gov identifier NCT01568892). At day 8, all subjects switched to open-label DTG 50 mg twice daily and optimized background therapy including ≥1 fully active drug. The primary end point was change from baseline in plasma HIV-1 RNA at day 8.
Results
The study population (n=30) was highly ART-experienced with advanced HIV disease. Patients had extensive baseline resistance to all approved antiretroviral classes. Adjusted mean change in HIV-1 RNA at day 8 was -1.06 log10 copies/ml for the DTG arm and 0.10 log10 copies/ml for the placebo arm (treatment difference -1.16 log10 copies/ml [-1.52, -0.80]; P<0.001). Overall, 47% and 57% of subjects had plasma HIV-1 RNA <50 and <400 copies/ml at week 24, and 40% and 53% at week 48, respectively. No discontinuations due to drug-related adverse events occurred in the study.
Conclusions
The observed day 8 antiviral activity in this highly treatment-experienced population with INI-resistant HIV-1 was attributable to DTG. Longer-term efficacy (after considering baseline ART resistance) and safety during the open-label phase were in-line with the results of the larger VIKING-3 study.
References
1.
Tivicay (dolutegravir).Package insert2013. ViiV HealthcareResearch Triangle Park, NC, USA.
2.
Tivicay (dolutegravir).Summary of product characteristics2013. ViiV Healthcare UK LtdMiddlesex, UK.
3.
RaffF., RachlisA., StellbrinkH.J.Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study.Lancet2013; 381: 735–743.
4.
CahnP., PozniakA.L., MingroneH.Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study.Lancet2013; 382: 700–708.
5.
WalmsleyS.L., AntelaA., ClumeckN.Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection.N Engl J Med2013; 369: 1807–1818.
6.
CastagnaA., MaggioloF., PencoG.Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study.J Infect Dis2014; 210: 354–362.
7.
DooleyK.E., SayreP., BorlandJ.Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a Phase 1 study among healthy subjects.J Acquir Immune Defic Syndr2013; 62: 21–27.
8.
VavroC., HuangJ., AvatapallyC.Durable efficacy and limited integrase resistance in subjects receiving dolutegravir after failing a prior INI regimen: week 48 results from VIKING-3.12th European Workshop on HIV & Hepatitis Treatment Strategies & Antiviral Drug Resistance. 26–28 March 2014, Barcelona, Spain. Abstract O_10.
